Avanafil: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Create Avanafil scaffold |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| Line 15: | Line 15: | ||
| legal = Rx-only in US | | legal = Rx-only in US | ||
| mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. | | mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. | ||
| intro = Avanafil is the newest of the four FDA-approved PDE5 inhibitors (2012). Compared to [[Sildenafil]] and [[Vardenafil]], it has a faster onset (~15 min) and is more selective for PDE5 over PDE6 (fewer visual side effects). Compared to [[Tadalafil]], it has a shorter duration | | intro = Avanafil is the newest of the four FDA-approved PDE5 inhibitors (2012). Compared to [[Sildenafil]] and [[Vardenafil]], it has a faster onset (~15 min) and is more selective for PDE5 over PDE6 (fewer visual side effects). Compared to [[Tadalafil]], it has a shorter duration, better suited to as-needed use than continuous coverage. | ||
| indications = | | indications = | ||
| dosing = | | dosing = | ||